Professor Manish Chand launches clinical feasibility study using SENSEI® in robot-assisted colorectal cancer surgery at University College Hospital, London.
Lightpoint announces positive clinical trial data for SENSEI® in prostate cancer surgery at the Annual Congress of the European Association of Nuclear Medicine. SENSEI® achieved 100% detection of sentinel lymph nodes in prostate cancer surgery and detected more sentinel nodes than a conventional gamma probe.
Dr Matthias Heck at the Technical University of Munich is the world's first surgeon to test SENSEI® in combination with PSMA in prostate cancer surgery.
Lightpoint signs commercial agreement with HOAM Medical (www.hoammedi.com) for distribution of SENSEI®, our miniature gamma probe for minimally-invasive and robot-assisted surgery, in South Korea.
The brilliant team at UZ Leuven completed their first patient to help us evaluate SENSEI®, our miniature gamma probe for minimally-invasive and robot assisted surgery, in the treatment of prostate cancer.
Lightpoint and Telix will work together to explore how Lightpoint's SENSEI® surgical probe and Telix's molecular imaging agents may be used together for real-time, intra-operative cancer detection.
Lightpoint has appointed Graeme Smith as CEO to focus on the commercialization of the company's recently approved miniaturized surgical probe, SENSEI®.
First clinical use of SENSEI® in robot-assisted cervical cancer surgery at UMC, Utrecht in the Netherlands using the da Vinci surgical robot.
Dr Jochen Walz and his team at the Institut Paoli-Calmettes in Marseille are the first team in France to use SENSEI® with the da Vinci surgical robot.
Lightpoint has secured $8 Million in new finance from the British Business Bank and follow-on investor.
Surgeon's Choice will be responsible for the distribution and sale of SENSEI® across Australia.
TECNASA, Technologias Asociadas will be responsible for the distribution and sale of SENSEI® in Spain and Portugal.
Dr Lluis Fumado and the team at Hospital del Mar, Barcelona, is the first to initiate in a multi-center clinical trial with SENSEI® in prostate cancer surgery.
SENSEI®, our miniaturized probe for minimally-invasive and robot-assisted cancer surgery, has been successfully registered with the FDA and is now authorized for sale in the US.
SENSEI®, Lightpoint's miniaturized probe designed for intra-operative detection of sentinel lymph nodes as well as cancer metastasis through the lymphatic system, has received regulatory approval in the EU.